Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPG 7909 plus Herceptin in metastatic breast cancer
NCT00043394Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2002
- Primary completion
- Oct 2003
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of agatolimod in breast cancer, sponsored by Pfizer. Started Sep 2002; status: completed.
02
Drugs
agatolimod
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00043394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043394.